Targets and genomic constraints of ectopic Dnmt3b expression.
Yingying ZhangJocelyn CharltonRahul KarnikIsabel BeermanZachary D SmithHongcang GuPatrick BoyleXiaoli MiM Kendell ClementRamona PopAndreas GnirkeDerrick J RossiAlexander MeissnerPublished in: eLife (2018)
DNA methylation plays an essential role in mammalian genomes and expression of the responsible enzymes is tightly controlled. Deregulation of the de novo DNA methyltransferase DNMT3B is frequently observed across cancer types, yet little is known about its ectopic genomic targets. Here, we used an inducible transgenic mouse model to delineate rules for abnormal DNMT3B targeting, as well as the constraints of its activity across different cell types. Our results explain the preferential susceptibility of certain CpG islands to aberrant methylation and point to transcriptional state and the associated chromatin landscape as the strongest predictors. Although DNA methylation and H3K27me3 are usually non-overlapping at CpG islands, H3K27me3 can transiently co-occur with DNMT3B-induced DNA methylation. Our genome-wide data combined with ultra-deep locus-specific bisulfite sequencing suggest a distributive activity of ectopically expressed Dnmt3b that leads to discordant CpG island hypermethylation and provides new insights for interpreting the cancer methylome.
Keyphrases
- dna methylation
- genome wide
- gene expression
- copy number
- papillary thyroid
- single cell
- poor prognosis
- mouse model
- squamous cell
- transcription factor
- electronic health record
- circulating tumor
- cell therapy
- lymph node metastasis
- stem cells
- cancer therapy
- mesenchymal stem cells
- drug induced
- drug delivery
- bone marrow
- childhood cancer
- mass spectrometry